Rituximab in Refractory Cutaneous Lupus
DOI:
https://doi.org/10.32818/reccmi.a5n3a8Keywords:
lupus, skin involment, rituximab.Abstract
Systemic lupus erythematosus is a chronic autoimmune disease of multiorgan commitment, uncommon in the male sex, where it occurs with greater morbidity. The clinical case of a man who debuts with severe systemic commitment, adding refractory bullous skin commitment to immunosuppressive treatment, with a good response after Rituximab.
Downloads
Metrics
References
Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(29): e4272. doi: https://doi.org/10.1097/MD.0000000000004272.
Crow MK. Etiology and Pathogenesis of Systemic Lupus Erythematosus, Tenth Edit, Elsevier Inc, 2017. doi: https://doi.org/10.1016/B978-0-323-31696-5.00079-6.
Sánchez-Navarro LM, Poletti ED, López-Domínguez NV, López SS, Sánchez- Delgado MA. Lupus eritematoso sistémico ampolloso: reporte de un caso y revisión de la literatura. DermatologíaCMQ. 2012; 10(3): 182-187. (Ultimo acceso Agosto 2020) Accesible en: https://www.medigraphic.com/pdfs/cosmetica/dcm-2012/dcm123e.pdf.
Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin. 2011; 29(4): 649-53. doi: https://doi.org/10.1016/j.det.2011.06.002.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6): 630-40. doi: https://doi.org/10.1002/art.1780350606.
Okon LG,WerthVP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013; 27(3): 391-404. doi: https://doi.org/10.1016/j.berh.2013.07.008.
Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus. Curr Opin Rheumatol. 2016; 28(5): 453-459. doi: https://doi.org/10.1097/BOR.0000000000000308.
Vico-Alonso C, Calleja-Algarra A, Andrés-Lencina JJ, Aragón-Miguel R, Pinilla-Martin B, Sánchez-Velázquez A, et al. Bullous eruption in a 1-year-old female in the Philippines: A diagnostic challenge. (Poster in American Academy of Dermatology 2019 Annual Meeting). J Am Acad Dermatol. 2017; 81(4) suppl.1: AB177. doi: https://doi.org/10.1016/j.jaad.2019.06.660.
de Risi-Pugliese T, Cohen Aubart F, Haroche J, Moguelet P, Grootenboer- Mignot S, Mathian A, et al. Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018; 48(1): 83-89. doi: https://doi.org/10.1016/j.semarthrit.2017.11.003.
Fruchter R, Kurtzman DJB, Patel M, Merola J, Franks AG Jr, Vleugels RA, et al. Characteristics and Alternative Treatment Outcomes of Antimalarial- Refractory Cutaneous Lupus Erythematosus. JAMA Dermatol. 2017; 153(9): 937-939. doi: https://doi.org/10.1001/jamadermatol.2017.1160.
Penha MÁ, Libório RDS, Miot HA. Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus. An Bras Dermatol. 2018; 93(3): 467-469. doi: https://doi.org/10.1590/abd1806-4841.20187561.
Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011; 17(3): 142-4. doi: https://doi.org/10.1097/RHU.0b013e318214f30c.
Akpabio AA, Otike-Odibi BI. Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa. Reumatismo. 2020 Jul 23;72(2):115-119. doi: https://doi.org/10.4081/reumatismo.2020.1274.
Cieza-Díaz DE, Avilés-Izquierdo JA, Ceballos-Rodríguez C, Suárez-Fernández R. Lupus eritematoso cutáneo subagudo refractario tratado con rituximab [Refractory subacute cutaneous lupus erythematosus treated with rituximab]. Actas Dermosifiliogr. 2012 Jul-Aug;103(6):555-7. doi: https://doi.org/10.1016/j.ad.2011.10.013.
Lowe CD, Brahe CA, Green B, Lam TK, Meyerle JH. Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis. 2019; 103(6): E5-E7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Mariana Cruz, Diego Carlos Graña-Cruz, Leticia Pérez, Javier Gaudiano
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
